Lung cancer is becoming a more common disease each year. It is the leading cause of cancer death all over the world. As a result, an alternate solution for treating and controlling lung cancer with minimum side effects is required. Therefore, our research goal was to develop a poly-herbal capsule formulation for the treatment and management of lung cancer disease. Poly-herbal formulation included hydroalcoholic (30:70) extracts (PHAE) from Ocimum sanctum, Curcuma longa, Emblica Officinalis, Teriminalia bellerica, Teriminalia chebula, Piper longum, Piper nigrum, and Zingiber officinale. The developed polyherbal capsule formulation was standardized according to WHO quality standardization requirements. The developed poly-herbal capsule formulation was evaluated using A549 lung cancer cell line, antioxidant, Fourier Transform Infra-Red (FTIR), and High-Performance Thin Layer Chromatography (HPTLC) methods. The antioxidant activity was measured with the DPPH (2, 2-diphenyl-1- picrylhydrazyl) and ferric ion reducing power assay (FRAC), and anticancer activity was estimated with (MTT) 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay method. The weight fluctuation and moisture analysis findings of pharmaceutical parameters were within regulatory limits. An in-vitro dissolution study indicated release rate of drug through the poly-herbal capsule was 98.67 percent in 30 minutes. The poly-herbal extract's activity in the DPPH and FRAC assays was comparable to that of conventional medication. In addition, against the A549 lung cancer cell line, the optimized finished poly-herbal formulation showed substantial cytotoxic action. The results of all emulation parameters revealed that it could be used for the treatment and management of lung cancer disease

lung cancer, poly-herbal formulation, A549 lung carcinoma cell line, hard gelatin capsul